Consolidation  	Consolidation  	 NN	B-NP
therapy  	therapy  	 NN	I-NP
in  	in  	 IN	O
ovarian  	ovarian  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
:  	:  	 :	O
a  	a  	 DT	O
clinical  	clinical  	 JJ	O
update  	update  	 NN	O
To  	To  	 TO	O
evaluate  	evaluate  	 VB	O
current  	current  	 JJ	O
strategies  	strategies  	 NNS	O
under  	under  	 IN	O
investigation  	investigation  	 NN	B-NP
for  	for  	 IN	O
use  	use  	 NN	O
as  	as  	 IN	O
consolidation  	consolidation  	 NN	B-NP
or  	or  	 CC	O
maintenance  	maintenance  	 NN	B-NP
treatment  	treatment  	 NN	I-NP
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
ovarian  	ovarian  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
.  	.  	 .	O
Patients  	Patients  	 NNS	O
with  	with  	 IN	O
epithelial  	epithelial  	 JJ	B-NP
ovarian  	ovarian  	 JJ	I-NP
cancer  	cancer  	 NN	I-NP
often  	often  	 RB	O
enter  	enter  	 VB	O
a  	a  	 DT	O
complete  	complete  	 JJ	O
remission  	remission  	 NN	O
after  	after  	 IN	O
primary  	primary  	 JJ	B-NP
treatment 	treatment 	 NN	I-NP
.  	.  	 .	O
Many  	Many  	 JJ	O
relapse 	relapse 	 NN	O
,  	,  	 ,	O
unfortunately 	unfortunately 	 RB	O
,  	,  	 ,	O
but  	but  	 CC	O
some  	some  	 DT	O
can  	can  	 MD	O
return  	return  	 VB	O
to  	to  	 TO	O
remission  	remission  	 VB	O
after  	after  	 IN	O
additional  	additional  	 JJ	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
Outcomes  	Outcomes  	 NNP	O
can  	can  	 MD	O
be  	be  	 VB	O
improved  	improved  	 VBN	O
by  	by  	 IN	O
applying  	applying  	 VBG	O
effective  	effective  	 JJ	O
consolidation  	consolidation  	 NN	B-NP
or  	or  	 CC	O
maintenance  	maintenance  	 NN	B-NP
approaches  	approaches  	 NNS	I-NP
to  	to  	 TO	O
patients  	patients  	 NNS	O
in  	in  	 IN	O
a  	a  	 DT	O
complete  	complete  	 JJ	O
primary  	primary  	 JJ	O
or  	or  	 CC	O
subsequent  	subsequent  	 JJ	O
remission 	remission 	 NN	O
.  	.  	 .	O
A  	A  	 DT	O
selective  	selective  	 JJ	B-NP
review  	review  	 NN	I-NP
of  	of  	 IN	O
the  	the  	 DT	O
literature  	literature  	 NN	O
is  	is  	 VBZ	O
undertaken  	undertaken  	 VBN	O
to  	to  	 TO	O
consider  	consider  	 VB	O
strategies  	strategies  	 NNS	O
that  	that  	 WDT	O
are  	are  	 VBP	O
being  	being  	 VBG	O
or  	or  	 CC	O
will  	will  	 MD	O
likely  	likely  	 RB	O
be  	be  	 VB	O
evaluated  	evaluated  	 VBN	O
in  	in  	 IN	O
randomized  	randomized  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
while  	while  	 IN	O
we  	we  	 PRP	O
assess  	assess  	 VBP	O
whether  	whether  	 IN	O
consolidation  	consolidation  	 NN	B-NP
or  	or  	 CC	O
maintenance  	maintenance  	 NN	O
will  	will  	 MD	O
have  	have  	 VB	O
a  	a  	 DT	O
place  	place  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
ovarian  	ovarian  	 JJ	B-NP
cancer 	cancer 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
application  	application  	 NN	O
of  	of  	 IN	O
extended  	extended  	 JJ	O
standard  	standard  	 JJ	O
cytotoxic  	cytotoxic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
has  	has  	 VBZ	O
been  	been  	 VBN	O
generally  	generally  	 RB	O
disappointing 	disappointing 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
no  	no  	 DT	O
strategy  	strategy  	 NN	O
applied  	applied  	 VBN	O
in  	in  	 IN	O
the  	the  	 DT	O
first  	first  	 JJ	O
remission  	remission  	 JJ	B-NP
setting  	setting  	 NN	I-NP
has  	has  	 VBZ	O
prolonged  	prolonged  	 VBN	O
overall  	overall  	 JJ	O
survival 	survival 	 NN	O
.  	.  	 .	O
As  	As  	 IN	O
treatment  	treatment  	 NN	B-NP
options  	options  	 NNS	I-NP
move  	move  	 VBP	O
beyond  	beyond  	 IN	O
classic  	classic  	 JJ	B-NP
chemotherapy  	chemotherapy  	 NN	I-NP
to  	to  	 TO	O
novel  	novel  	 NN	O
hormones 	hormones 	 NNS	O
,  	,  	 ,	O
immune  	immune  	 JJ	O
interventions 	interventions 	 NNS	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
biologic  	biologic  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
consolidation  	consolidation  	 NN	B-NP
strategy  	strategy  	 NN	I-NP
is  	is  	 VBZ	O
regaining  	regaining  	 VBG	B-NP
interest 	interest 	 NN	I-NP
.  	.  	 .	O
This  	This  	 DT	O
is  	is  	 VBZ	O
particularly  	particularly  	 RB	O
attractive  	attractive  	 JJ	O
in  	in  	 IN	O
that  	that  	 DT	O
many  	many  	 JJ	O
of  	of  	 IN	O
these  	these  	 DT	O
agents  	agents  	 NNS	O
have  	have  	 VBP	O
stable  	stable  	 JJ	O
disease  	disease  	 NN	O
as  	as  	 IN	O
best  	best  	 JJS	O
outcome 	outcome 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
this  	this  	 DT	O
is  	is  	 VBZ	O
most  	most  	 RBS	O
appropriate  	appropriate  	 JJ	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
in  	in  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
minimal  	minimal  	 JJ	O
volume  	volume  	 NN	B-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
consideration  	consideration  	 NN	B-NP
of  	of  	 IN	O
toxicity  	toxicity  	 NN	O
is  	is  	 VBZ	O
paramount 	paramount 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
any  	any  	 DT	O
strategy  	strategy  	 NN	O
to  	to  	 TO	O
be  	be  	 VB	O
considered  	considered  	 VBN	O
in  	in  	 IN	O
an  	an  	 DT	O
otherwise  	otherwise  	 RB	O
asymptomatic  	asymptomatic  	 JJ	B-NP
patient  	patient  	 NN	I-NP
in  	in  	 IN	O
remission  	remission  	 NNS	O
must  	must  	 MD	O
be  	be  	 VB	O
well  	well  	 RB	O
tolerated 	tolerated 	 VBN	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
patients  	patients  	 NNS	O
in  	in  	 IN	O
second  	second  	 JJ	O
or  	or  	 CC	O
third  	third  	 JJ	O
complete  	complete  	 JJ	O
remission  	remission  	 NNS	O
are  	are  	 VBP	O
also  	also  	 RB	O
being  	being  	 VBG	O
considered  	considered  	 VBN	O
as  	as  	 IN	O
an  	an  	 DT	O
appropriate  	appropriate  	 JJ	O
group  	group  	 NN	O
in  	in  	 IN	O
which  	which  	 WDT	O
to  	to  	 TO	O
evaluate  	evaluate  	 VB	O
new  	new  	 JJ	O
agents 	agents 	 NNS	O
.  	.  	 .	O
Numerous  	Numerous  	 JJ	B-NP
other  	other  	 JJ	I-NP
phase  	phase  	 NN	I-NP
2  	2  	 CD	O
trials  	trials  	 NNS	O
with  	with  	 IN	O
novel  	novel  	 NN	O
agents  	agents  	 NNS	O
not  	not  	 RB	O
considered  	considered  	 VBN	O
here  	here  	 RB	O
are  	are  	 VBP	O
underway 	underway 	 VBN	O
,  	,  	 ,	O
and  	and  	 CC	O
it  	it  	 PRP	O
is  	is  	 VBZ	O
to  	to  	 TO	O
be  	be  	 VB	O
hoped  	hoped  	 VBN	O
that  	that  	 IN	O
some  	some  	 DT	O
will  	will  	 MD	O
emerge  	emerge  	 VB	O
as  	as  	 IN	O
contenders  	contenders  	 NNS	O
for  	for  	 IN	O
randomized  	randomized  	 JJ	B-NP
trials 	trials 	 NNS	I-NP
.  	.  	 .	O
Participation  	Participation  	 NN	B-NP
in  	in  	 IN	O
these  	these  	 DT	O
trials  	trials  	 NN	O
remains  	remains  	 VBZ	O
a  	a  	 DT	O
priority  	priority  	 NN	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
who  	who  	 WP	O
otherwise  	otherwise  	 RB	O
must  	must  	 MD	O
pursue  	pursue  	 VB	O
a  	a  	 DT	O
difficult  	difficult  	 JJ	O
watch-and-wait  	watch-and-wait  	 JJ	B-NP
strategy 	strategy 	 NN	I-NP
.  	.  	 .	O
